Well.... nice to see you back on SUD threads again Sth! Although...

Well.... nice to see you back on SUD threads again Sth!

Although I must confess to having been stalking you whilst you have been giving it to a variety of Ozzie biotechs on HC. Of particular interest is when it comes to discussing the nuances of clinical trials and the interpretation of resulting datasets from the same. If SUD ever gets around to doing something useful in the way of exploratory or confirmatory trials then remind me that I am not to engage you in ANY scientific discourse. On that matter, I for one am real glad that you didn't run the ruler over the artimist PhIII trial from various locales in Afrika. I suspect that some questionable science from those trials may be the reason for a variety of delays from national and international health authorities.

Anyway, despite my long held opinion that zolpi is a crap product that is highly addictive and in no small part contributes to the fool that is Elon Musk and a variety of other luminaries including our own swim stars, the lack of a patent is new news for me. It suspect that it doesn't really matter too much however, I reckon that Eddingpharm has all ready slipped a coupla vials to some Chinese state owned outfit, who have cloned it and are preparing to sell it legally or otherwise globally.

Implicit in Carter's recent machinations, which I suspect are not influenced by his own Zolpi product, is a move to eke out a margin by middle-manning between manufacturer and licensee. Rechon would be a reasonable candidate for that purpose, although I do remember that dialogue was held with another manufacturer some years ago for artimist and after those filthy krauts fell over and for which we are still paying the debt. No fault of Carter's of course except that he maintained on annual reports for about a decade that there was no material liability for the company. I'm not sure that due diligence is high on his corporate governance agenda.

Anyway, this latest update on Anagrelide adds a new market to the platform, as a prophylactic in certain susceptible persons no less. All good and will certainly add to the value of the product in the event that someone wants to buy it.

As for the share price well Carter would have been better off jumping up and down about the recent Aytu news and promoting the company on shareholders behalf, which is his fcn job.

Anyway Sth, always good to read your posts, on any threads. Stay well and out of the heat. Have you got any power in that State yet?